Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species

被引:25
作者
Pfaller, MA
Messer, SA
Mills, K
Bolmström, A
Jones, RN
机构
[1] Univ Iowa, Coll Med, Dept Pathol, Div Med Microbiol, Iowa City, IA 52242 USA
[2] Univ Iowa, Coll Med, CAST Lab, Iowa City, IA USA
[3] JONES Grp, Iowa City, IA USA
[4] AB BIODISK, Solna, Sweden
关键词
D O I
10.1128/JCM.39.11.3952-3954.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The performance of the Etest for posaconazole (SCH 56592) susceptibility testing of 314 isolates of Candida spp. was assessed against the National Committee for Clinical Laboratory Standards (NCCLS) microdilution broth method. The NCCLS method employed RPMI 1640 broth medium, and MICs were read after incubation for 48 h at 35 degreesC. MICs were determined by Etest for all 314 isolates with RPMI agar containing 2% glucose (RPG agar) and were read after incubation for 48 h at 35 degreesC. The Candida isolates included C. albicans (n = 174), C. glabrata (n = 57), C. tropicalis (n = 31), C. parapsilosis (n = 39), C. krusei (n = 5), C. guilliermondii (n = 6), and C. lusitaniae (n = 2). The Etest results correlated well with reference MICs. Overall agreement was 95%, and agreements for individual species were as follows: C. krusei, 100%; C. albicans, 98%; C. tropicalis, 97%; C. glabrata, 93%; C. parapsilosis, 85%; C. guilliermondii, 83%; and C. lusitaniae, 50%. The problem of trailing end points was minimized with RPG agar, and good agreement with broth dilution MICs was obtained when discernible growth within an established ellipse was ignored. The Etest method using RPG agar appears to be a useful method for determining posaconazole susceptibilities of Candida species.
引用
收藏
页码:3952 / 3954
页数:3
相关论文
共 19 条
  • [1] In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens
    Barchiesi, F
    Arzeni, D
    Fothergill, AW
    Di Francesco, LF
    Caselli, F
    Rinaldi, MG
    Scalise, G
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) : 226 - 229
  • [2] Quality control limits for broth microdilution susceptibility tests of ten antifungal agents
    Barry, AL
    Pfaller, MA
    Brown, SD
    Espinel-Ingroff, A
    Ghannoum, MA
    Knapp, C
    Rennie, RP
    Rex, JH
    Rinaldi, MG
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (09) : 3457 - 3459
  • [3] In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida
    Cacciapuoti, A
    Loebenberg, D
    Corcoran, E
    Menzel, F
    Moss, EL
    Norris, C
    Michalski, M
    Raynor, K
    Halpern, J
    Mendrick, C
    Arnold, B
    Antonacci, B
    Parmegiani, R
    Yarosh-Tomaine, T
    Miller, GH
    Hare, RS
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) : 2017 - 2022
  • [4] EVALUATION OF THE E-TEST SYSTEM VERSUS A MICROTITRE BROTH METHOD FOR ANTIFUNGAL SUSCEPTIBILITY TESTING OF YEASTS AGAINST FLUCONAZOLE AND ITRACONAZOLE
    COLOMBO, AL
    BARCHIESI, F
    MCGOUGH, DA
    FOTHERGILL, AW
    RINALDI, MG
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 (01) : 93 - 100
  • [5] Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
    Espinel-Ingroff, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) : 2950 - 2956
  • [6] Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose
    EspinelIngroff, A
    Pfaller, M
    Erwin, ME
    Jones, RN
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (04) : 848 - 852
  • [7] ESPINELINGROFF A, 1999, MANUAL CLIN MICROBIO, P1640
  • [8] In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts
    Galgiani, JN
    Lewis, ML
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) : 180 - 183
  • [9] Jorgenson J. H., 1999, MANUAL CLIN MICROBIO, P1526
  • [10] National Committee for Clinical Laboratory Standards, 1997, M27A NAT COMM CLIN L